The Role of Transurethral Resection In Trimodal Therapy for Muscle-Invasive Bladder Cancer

Overview

Journal Bladder Cancer

Publisher IOS Press

Date 2016 Dec 31

PMID 28035319

Citations 7

Authors

Christopher M Russell

Amir H Lebastchi

Tudor Borza

Daniel E Spratt

Todd M Morgan

Affiliations

Soon will be listed here.

Abstract

While radical cystectomy (RC) with pelvic lymph node dissection (PLND) represents the accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment approach is associated with significant morbidity. As such, bladder preservation strategies are often utilized in patients who are either deemed medically unfit due to significant comorbidities or whom decline management with RC and PLND secondary to its associated morbidity. In a select group of patients, meeting strict criteria, bladder preservation approaches may be employed with curative intent. Trimodal therapy, consisting of complete transurethral resection of bladder tumor (TURBT), chemotherapy, and radiation therapy has demonstrated durable oncologic control and long-term survival in a number of studies. The review presented here provides a description of trimodal therapy and the role of TURBT in bladder preservation for patients with muscle-invasive bladder cancer.

Citing Articles

The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.

Sheybaee Moghaddam F, Dwabe S, Mar N, Safdari L, Sabharwal N, Goldberg H Cancers (Basel). 2024; 16(19).

PMID: 39409980 PMC: 11475991. DOI: 10.3390/cancers16193361.

Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.

Luo C, Luo S, Wusimanjiang W, Wang Z, Liu P, Wang B Clin Transl Oncol. 2024; 26(7):1759-1767.

PMID: 38472556 DOI: 10.1007/s12094-024-03400-z.

A multidisciplinary discussion of BladderPath.

St-Laurent M, Sfakianos J, Rose T, Chung P, Kassouf W, Zlotta A Can Urol Assoc J. 2023; 18(3):E91-E92.

PMID: 38010224 PMC: 10954283. DOI: 10.5489/cuaj.8525.

Positive Association of Matrix Proteins Alteration with TAZ and The Progression of High-Grade Bladder Cancer.

Ghassemi H, Hashemnia M, Mousavibahar S, Mahmoodzadeh Hosseini H, Mirhosseini S Cell J. 2022; 23(7):742-749.

PMID: 34979063 PMC: 8753103. DOI: 10.22074/cellj.2021.7661.

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.

Hamad J, McCloskey H, Milowsky M, Royce T, Smith A Int Braz J Urol. 2020; 46(2):169-184.

PMID: 31961624 PMC: 7025842. DOI: 10.1590/S1677-5538.IBJU.2020.99.01.

References

Smith Z, Christodouleas J, Keefe S, Malkowicz S, Guzzo T . Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013; 112(1):13-25. DOI: 10.1111/j.1464-410X.2012.11762.x. View

Lin C, Hsu C, Cheng J, Huang C, Tsai Y, Hsu F . Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2009; 75(2):442-8. DOI: 10.1016/j.ijrobp.2008.11.030. View

Arias F, Dominguez M, Martinez E, Illarramendi J, Miquelez S, Pascual I . Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys. 2000; 47(2):373-8. DOI: 10.1016/s0360-3016(00)00444-2. View

Pollack A, Zagars G, Swanson D . Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys. 1994; 30(2):267-77. DOI: 10.1016/0360-3016(94)90004-3. View

Herr H . The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999; 162(1):74-6. DOI: 10.1097/00005392-199907000-00018. View

Weiss C, Wittlinger M, Engehausen D, Krause F, Ott O, Dunst J . Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys. 2007; 70(5):1502-6. DOI: 10.1016/j.ijrobp.2007.08.007. View

Rodel C, Grabenbauer G, Kuhn R, Papadopoulos T, Dunst J, Meyer M . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14):3061-71. DOI: 10.1200/JCO.2002.11.027. View

Krause F, Walter B, Ott O, Haberle L, Weiss C, Rodel C . 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011; 31(3):985-90. View

Jichlinski P, Leisinger H . Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist!. Urol Int. 2005; 74(2):97-101. DOI: 10.1159/000083277. View

10.

Watts K, Ristau B, Yamase H, Taylor 3rd J . Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods?. BJU Int. 2011; 108(4):484-92. DOI: 10.1111/j.1464-410X.2011.10330.x. View

11.

Mariappan P, Finney S, Head E, Somani B, Zachou A, Smith G . Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation.... BJU Int. 2011; 109(11):1666-73. DOI: 10.1111/j.1464-410X.2011.10571.x. View

12.

Henningsohn L, Steven K, Kallestrup E, Steineck G . Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol. 2002; 168(1):168-74; discussion 174-5. DOI: 10.1016/s0022-5347(05)64854-9. View

13.

Venkatramani V, Panda A, Manojkumar R, Kekre N . Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol. 2013; 191(6):1703-7. DOI: 10.1016/j.juro.2013.12.004. View

14.

Hagan M, Winter K, Kaufman D, Wajsman Z, Zietman A, Heney N . RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003; 57(3):665-72. DOI: 10.1016/s0360-3016(03)00718-1. View

15.

Madersbacher S, Hochreiter W, Burkhard F, Thalmann G, Danuser H, Markwalder R . Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21(4):690-6. DOI: 10.1200/JCO.2003.05.101. View

16.

Hussain S, Stocken D, Peake D, Glaholm J, Zarkar A, Wallace D . Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004; 90(11):2106-11. PMC: 2409507. DOI: 10.1038/sj.bjc.6601852. View

17.

Zapatero A, de Vidales C, Arellano R, Ibanez Y, Bocardo G, Perez M . Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology. 2012; 80(5):1056-62. DOI: 10.1016/j.urology.2012.07.045. View

18.

Chen R, Shipley W, Efstathiou J, Zietman A . Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013; 11(8):952-60. DOI: 10.6004/jnccn.2013.0116. View

19.

Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debre B, Zerbib M . Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004; 63(1):73-7. DOI: 10.1016/j.urology.2003.09.018. View

20.

Efstathiou J, Spiegel D, Shipley W, Heney N, Kaufman D, Niemierko A . Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2011; 61(4):705-11. DOI: 10.1016/j.eururo.2011.11.010. View